BETA
BETA
Sage Therapeutics
SAGE72
$10.99arrow_drop_up4.96%$0.52
SAGE72
$10.99
arrow_drop_up4.96%Performance History
| Key Stats | |
|---|---|
| Open | $10.64 |
| Prev. Close | $10.47 |
| EPS | -8.39 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 10.49 | 10.99 |
| 52 Week Range | 9.73 | 41.67 |
| Ratios | |
|---|---|
| EPS | -8.39 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
Correlated Companies
About Sage Therapeutics (SAGE)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Barry E. Greene
- Headquarters
- Cambridge
- Employees
- 689
- Exchange
- NASDAQ
Keep an eye on Sage Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Sage Therapeutics 's (SAGE) price per share?
The current price per share for Sage Therapeutics (SAGE) is $10.99. The stock has seen a price change of $0.52 recently, indicating a 4.97% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Sage Therapeutics (SAGE)?
For Sage Therapeutics (SAGE), the 52-week high is $41.67, which is 279.16% from the current price. The 52-week low is $9.73, the current price is 12.95% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Sage Therapeutics (SAGE) a growth stock?
Sage Therapeutics (SAGE) has shown an average price growth of 0.41% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sage Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Sage Therapeutics (SAGE) stock price performance year to date (YTD)?
As of the latest data, Sage Therapeutics (SAGE) has a year-to-date price change of -51.11%. Over the past month, the stock has experienced a price change of 0.83%. Over the last three months, the change has been -19.07%. Over the past six months, the figure is -58.17%. Looking at a longer horizon, the five-year price change stands at -93.19%.
help
Is Sage Therapeutics (SAGE) a profitable company?
Sage Therapeutics (SAGE) has a net income of -$541.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.49K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $86.46M, although specific revenue growth data is currently not available. The gross profit is $84.3M. Operating income is noted at -$579.85M. Furthermore, the EBITDA is -$507.26M.
help
What is the market capitalization of Sage Therapeutics (SAGE)?
Sage Therapeutics (SAGE) has a market capitalization of $650.87M. The average daily trading volume is 1.09M, indicating the stock's liquidity and investor engagement.
News
SAGE THERAPEUTICS
ZURZUVAE
BIOGEN
MIZUHO SECURITIES
7/20/2024Mizuho cuts Sage Therapeutics stock target By Investing.com - Investing.com Australia
NETFLIX
ROBINHOOD
INTUITIVE SURGICAL
BANNER CORPORATION
D.R. HORTON
SAGE THERAPEUTICS
M&T BANK CORPORATION
DOMINO'S PIZZA
ARM HOLDINGS
JPMORGAN CHASE
7/19/2024Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
SAGE THERAPEUTICS
ANALYST RATINGS
PRICE TARGETS
FINANCIALS
7/12/2024Analyst Expectations For Sage Therapeutics's Future - Benzinga
6/12/2024
SAGE's Huntington's Disease Study Meets Primary Endpoint
ANALYST RATINGS
5/29/2024Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
4/26/2024
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.